Hemotune Secures CHF 14 Million for Clinical Trials

Hemotune obtient 14 millions de francs suisses pour ses essais cliniques

mar, 26 mars 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

Articles connexes

Vetropack Layoffs: Employees Demand Compensation

16 mai 2024

Amid planned layoffs, Vetropack employees push for a social plan and the preservation of jobs at the Saint-Prex site....

Weltwoche Must Remove Illegal Recording Zurich Court Deems

15 mai 2024

"Weltwoche" magazine removes content after Zurich judge's legal action against unauthorised recording during a court...

Council of States: Cutting Asylum Credits

16 mai 2024

Swiss Council of States committee recommends slashing the Federal Council's proposed funding for asylum centres by CHF...

Swiss Insurance Helvetia Restructuring

16 mai 2024

Helvetia Insurance adapts its executive management and structure to boost international operations and innovation, with...

Sunflower Oil Prices in Switzerland Remain High

14 mai 2024

Despite global declines in sunflower oil prices, Swiss consumers still pay significantly more, raising concerns about...

University Of Geneva Want To Prosecute Students: More Palestine Protests

14 mai 2024

Swiss universities experience protests demanding academic boycotts of Israeli institutions and the removal of Israeli...

Avalanche Claims Two Lives in Valais

19 mai 2024

Two alpinists died in a Whit Sunday avalanche in the Valais Alps, Valais police confirmed....

Rester en contact

À noter

Swiss Politician Charged With Faking Covid Certificates

À noter

1er mai 2024

Un politicien suisse accusé d'avoir falsifié des certificats Covid

Credit Suisse CEO To Step Down As UBS Merger Accelerates

À noter

6 mai 2024

Hemotune obtient 14 millions de francs suisses pour ses essais cliniques

Hemotune obtient 14 millions de francs suisses pour ses essais cliniques

Articles connexes

Rester en contact

À noter

Un politicien suisse accusé d'avoir falsifié des certificats Covid

Credit Suisse CEO To Step Down As UBS Merger Accelerates

Liens rapides